{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:20:39Z","timestamp":1783124439150,"version":"3.54.6"},"reference-count":292,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023731","name":"Regional Government of Andalusia Ministry of Health and Consumer Affairs","doi-asserted-by":"publisher","award":["PY20\/01282"],"award-info":[{"award-number":["PY20\/01282"]}],"id":[{"id":"10.13039\/501100023731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011011","name":"Junta de Andaluc\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI20\/01845"],"award-info":[{"award-number":["PI20\/01845"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["DTS23\/00030"],"award-info":[{"award-number":["DTS23\/00030"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI17\/02256"],"award-info":[{"award-number":["PI17\/02256"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.tranon.2026.102796","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:51:50Z","timestamp":1777636310000},"page":"102796","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Genetic architecture of multiple myeloma: From somatic alterations to germline susceptibility and clinical implications"],"prefix":"10.1016","volume":"69","author":[{"given":"Mar\u00eda","family":"Carretero-Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0346-7960","authenticated-orcid":false,"given":"Antonio Jos\u00e9","family":"Cabrera-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3575-5093","authenticated-orcid":false,"given":"Luc\u00eda Ru\u00edz","family":"Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Iba\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9358-6948","authenticated-orcid":false,"given":"Marco","family":"Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1374-0756","authenticated-orcid":false,"given":"Juan Francisco","family":"Guti\u00e9rrez-Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Chahboun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3438-0753","authenticated-orcid":false,"given":"Fernando Jes\u00fas","family":"Reyes-Zurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8205-6192","authenticated-orcid":false,"given":"Rosa","family":"Collado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9355-2423","authenticated-orcid":false,"given":"Juan","family":"Sainz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.102796_bib0138","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.tranon.2026.102796_bib0189","doi-asserted-by":"crossref","first-page":"6998","DOI":"10.1182\/blood-2024-211305","article-title":"Evolving burden of multiple myeloma and its trend in European Union countries from 1990 to 2021: a secondary analysis from the Global Burden of Disease Study 2021","volume":"144","author":"Modi","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0277","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival","volume":"101","author":"Turesson","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.tranon.2026.102796_bib0218","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/ajh.25117","article-title":"Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management","volume":"93","author":"Rajkumar","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tranon.2026.102796_bib0141","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0232","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.canep.2015.08.002","article-title":"Trends in survival of multiple myeloma: a thirty-year population-based study in a single institution","volume":"39","author":"R\u00edos-Tamayo","year":"2015","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.tranon.2026.102796_bib0063","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3390\/cancers13071686","article-title":"Emerging therapeutic strategies to overcome drug resistance in multiple myeloma","volume":"13","author":"Davis","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2026.102796_bib0258","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.973836","article-title":"Drug resistance in multiple myeloma: soldiers and weapons in the bone marrow niche","volume":"12","author":"Solimando","year":"2022","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.tranon.2026.102796_bib0223","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s43018-024-00784-3","article-title":"The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities","volume":"5","author":"Ramberger","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.tranon.2026.102796_bib0012","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group Consensus recommendations on the definition of high-risk multiple Myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102796_bib0036","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.3109\/10428194.2012.691483","article-title":"Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients","volume":"53","author":"Butler","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.tranon.2026.102796_bib0292","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2019-130079","article-title":"The spectrum of exomic mutation in elderly myeloma differs substantially from patients at younger ages consistent with a different evolutionary trajectory to full blown disease based on age of onset","volume":"134","author":"Williams","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0087","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e20052","article-title":"Identifying associations between race and gender in the incidence and mortality of patients with multiple myeloma","volume":"41","author":"Ghosh","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102796_bib0162","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/jnci\/djae321","article-title":"The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045","volume":"117","author":"Mafra","year":"2025","journal-title":"JNCI"},{"key":"10.1016\/j.tranon.2026.102796_bib0024","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.clml.2021.04.013","article-title":"Sex differences in multiple myeloma biology but not clinical outcomes: results from 3894 patients in the Myeloma XI trial","volume":"21","author":"Bird","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.tranon.2026.102796_bib0287","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.tranon.2026.102796_bib0094","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/leu.2011.368","article-title":"Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites","volume":"26","author":"Greenberg","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0110","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-41223-8","article-title":"Disentangling age, gender, and racial\/ethnic disparities in multiple myeloma burden: a modeling study","volume":"14","author":"Huber","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102796_bib0052","doi-asserted-by":"crossref","DOI":"10.1186\/s12920-025-02116-5","article-title":"Genomic characteristics and prognostic correlations in Chinese multiple myeloma patients","volume":"18","author":"Chen","year":"2025","journal-title":"BMC Med. Genom."},{"key":"10.1016\/j.tranon.2026.102796_bib0068","first-page":"28","article-title":"The age-dependent changes in risk weights of the prognostic factors for multiple myeloma","author":"Du","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.tranon.2026.102796_bib0069","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-140718","article-title":"The relative risk of prognostic factors of age stratified multiple myeloma","volume":"136","author":"Du","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0222","doi-asserted-by":"crossref","first-page":"6889","DOI":"10.1182\/blood-2024-203107","article-title":"Secure: a prospective long-term observational study in patients with monoclonal gammopathy of undetermined significance","volume":"144","author":"Ramasamy","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0140","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/jamaoncol.2019.1568","article-title":"Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"5","author":"Landgren","year":"2019","journal-title":"JAMa Oncol."},{"key":"10.1016\/j.tranon.2026.102796_bib0261","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/10428194.2025.2576562","article-title":"Risk stratification and early intervention in smoldering multiple myeloma","volume":"67","author":"Sra","year":"2026","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.tranon.2026.102796_bib0085","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10184179","article-title":"Occupational exposure and Multiple myeloma risk: an updated review of meta-analyses","volume":"10","author":"Georgakopoulou","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.tranon.2026.102796_bib0130","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/(SICI)1097-0274(199711)32:5<510::AID-AJIM11>3.0.CO;2-5","article-title":"Meta-analyses of Multiple myeloma and farming","volume":"32","author":"Khuder","year":"1997","journal-title":"J. Ind. Med"},{"key":"10.1016\/j.tranon.2026.102796_bib0245","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.clml.2015.06.003","article-title":"Risk factors for Multiple myeloma: a systematic review of meta-analyses","volume":"15","author":"Sergentanis","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.tranon.2026.102796_bib0142","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/bloodadvances.2023010843","article-title":"Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population","volume":"8","author":"Lee","year":"2024","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.tranon.2026.102796_bib0170","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41416-018-0010-4","article-title":"Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts","volume":"118","author":"Marinac","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tranon.2026.102796_bib0269","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.semcancer.2023.04.003","article-title":"Obesity and multiple myeloma: emerging mechanisms and perspectives","volume":"92","author":"Tentolouris","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.tranon.2026.102796_bib0211","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1002\/ijc.27898","article-title":"Tobacco smoking and risk of multiple myeloma: a meta-analysis of 40 observational studies","volume":"132","author":"Psaltopoulou","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tranon.2026.102796_bib0090","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jnci\/djy091","article-title":"An integrative approach for deciphering the causal associations of physical activity and cancer risk: the role of adiposity","volume":"110","author":"Giovannucci","year":"2018","journal-title":"JNCI"},{"key":"10.1016\/j.tranon.2026.102796_bib0123","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.clml.2024.04.006","article-title":"T cell exhaustion markers in multiple myeloma patients are lower after physical activity intervention","volume":"24","author":"Joseph","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.tranon.2026.102796_bib0045","doi-asserted-by":"crossref","unstructured":"Castro, F., Parikh, R., Eustaquio, J.C., Derkach, A., Joseph, J.M., Lesokhin, A.M., Usmani, S.Z., Shah, U.A., 2023. Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP diet and Health study. medRxiv 2023.09.20.23295639. https:\/\/doi.org\/10.1101\/2023.09.20.23295639.","DOI":"10.1101\/2023.09.20.23295639"},{"issue":"9","key":"10.1016\/j.tranon.2026.102796_bib0114","doi-asserted-by":"crossref","DOI":"10.1007\/s00520-023-08021-w","article-title":"Prevalence and clinical outcomes of vitamin D deficiency among Japanese multiple myeloma patients: a single-center observational study","volume":"31","author":"Isoda","year":"2023","journal-title":"Supportive Care in Cancer"},{"key":"10.1016\/j.tranon.2026.102796_bib0152","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/jvh.12742","article-title":"Hepatitis C virus infection and risk of multiple myeloma: evidence from a meta-analysis based on 17 case-control studies","volume":"24","author":"Li","year":"2017","journal-title":"J. Viral. Hepat."},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0299","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1186\/s12885-025-14420-5","article-title":"Hepatitis B and C virus infection and risk of multiple myeloma: a systematic review and meta-analysis","volume":"25","author":"Zamani","year":"2025","journal-title":"BMC. Cancer"},{"key":"10.1016\/j.tranon.2026.102796_bib0233","first-page":"13","article-title":"Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy","author":"Rodr\u00edguez-Garc\u00eda","year":"2025","journal-title":"Microbiome"},{"key":"10.1016\/j.tranon.2026.102796_bib0301","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.21037\/tcr.2020.03.36","article-title":"Type 2 diabetes mellitus does not increase the risk of multiple myeloma: a systematic review and meta-analysis","volume":"9","author":"Zhang","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102796_bib0302","article-title":"Causal associations between the gut microbiota and multiple myeloma: a two-sample mendelian randomization study","volume":"11","author":"Zhang","year":"2024","journal-title":"Front. Nutr."},{"key":"10.1016\/j.tranon.2026.102796_bib0182","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1158\/1055-9965.EPI-13-0695","article-title":"Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review","volume":"23","author":"McShane","year":"2014","journal-title":"Cancer Epidemiol. Biomarkers Prevent."},{"key":"10.1016\/j.tranon.2026.102796_bib0119","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10238-024-01327-x","article-title":"The casual relationship between autoimmune diseases and multiple myeloma: a Mendelian randomization study","volume":"24","author":"Jin","year":"2024","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0105","doi-asserted-by":"crossref","DOI":"10.1186\/1756-8722-5-59","article-title":"Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma","volume":"5","author":"Hemminki","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tranon.2026.102796_bib0129","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1182\/blood-2018-99-115672","article-title":"Association between monoclonal gammopathy and rheumatoid arthritis: a national inpatient sample (NIS) study","volume":"132","author":"Khan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0198","article-title":"Investigation of periodontal condition, and tooth loss in multiple myeloma patients: a case-control study","volume":"4","year":"2024","journal-title":"Journal of Dentistry and Oral Epidemiology"},{"key":"10.1016\/j.tranon.2026.102796_bib0236","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2014-10-609461","article-title":"Future distribution of multiple myeloma in the United States by sex, age, and race\/ethnicity","volume":"125","author":"Rosenberg","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0031","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1158\/1055-9965.EPI-11-0157","article-title":"Gender disparities in the tumor genetics and clinical outcome of multiple myeloma","volume":"20","author":"Boyd","year":"2011","journal-title":"Cancer Epidemiol. Biomarkers Prevent."},{"key":"10.1016\/j.tranon.2026.102796_bib0021","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1022268103136","article-title":"Myeloma and race: a review of the literature","volume":"22","author":"Benjamin","year":"2003","journal-title":"Cancer Metastasis Rev."},{"issue":"8","key":"10.1016\/j.tranon.2026.102796_bib0157","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.55","article-title":"Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis","volume":"4","author":"Lu","year":"2014","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tranon.2026.102796_bib0216","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bjh.13942","article-title":"Retrospective study of the incidence and patterns of arterial and venous thrombosis in Chinese versus African American patients with multiple myeloma","volume":"176","author":"Raghupathy","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.tranon.2026.102796_bib0139","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tranon.2026.102796_bib0006","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.ejca.2005.11.033","article-title":"Familial risks and temporal incidence trends of multiple myeloma","volume":"42","author":"Altieri","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tranon.2026.102796_bib0278","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2008-12-192575","article-title":"Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance","volume":"114","author":"Vachon","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0101","article-title":"Management of patients with Hepatitis C virus, monoclonal gammopathy of undetermined significance, and multiple myeloma","volume":"5","author":"Hannaford","year":"2017","journal-title":"J. Investig. Med. High. Impact. Case Rep."},{"key":"10.1016\/j.tranon.2026.102796_bib0150","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.celrep.2017.08.062","article-title":"Genetic predisposition to multiple myeloma at 5q15 is mediated by an ELL2 enhancer polymorphism","volume":"20","author":"Li","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.tranon.2026.102796_bib0234","first-page":"272","article-title":"Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses","volume":"109","author":"Rodr\u00edguez-Garc\u00eda","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.tranon.2026.102796_bib0086","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/hematolrep17060056","article-title":"The gut microbiome role in multiple myeloma: emerging insights and therapeutic opportunities","volume":"17","author":"George","year":"2025","journal-title":"Hematol. Rep."},{"key":"10.1016\/j.tranon.2026.102796_bib0210","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/bloodadvances.2019032276","article-title":"Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition","volume":"3","author":"Pianko","year":"2019","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0066","doi-asserted-by":"crossref","DOI":"10.1038\/srep32063","article-title":"Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis","volume":"6","author":"Deng","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tranon.2026.102796_bib0044","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41375-023-02132-3","article-title":"Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP diet and health study","volume":"38","author":"Castro","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.102796_bib0247","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1158\/1078-0432.CCR-22-0723","article-title":"Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets","volume":"28","author":"Shah","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102796_bib0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/j.seminhematol.2024.11.006","article-title":"FaMMily Affairs: dissecting inherited contributions to multiple myeloma risk","volume":"62","author":"Bodnar","year":"2025","journal-title":"Semin. Hematol."},{"issue":"3","key":"10.1016\/j.tranon.2026.102796_bib0207","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41375-019-0703-6","article-title":"Genetic predisposition for multiple myeloma","volume":"34","author":"Pertesi","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.102796_bib0262","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1080\/10428194.2025.2516256","article-title":"Familial aspects of multiple myeloma and Waldenstr\u00f6m macroglobulinemia: understanding the predisposition in relatives and the importance of early diagnosis","volume":"66","author":"Sternbach","year":"2025","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.tranon.2026.102796_bib0098","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/jha2.557","article-title":"A germline exome analysis reveals harmful POT1 variants in multiple myeloma patients and families","volume":"3","author":"Hakkarainen","year":"2022","journal-title":"EJHaem."},{"issue":"9","key":"10.1016\/j.tranon.2026.102796_bib0206","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1038\/s41375-019-0452-6","article-title":"Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma","volume":"33","author":"Pertesi","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.102796_bib0177","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111620","article-title":"Germline predisposition in multiple myeloma","volume":"28","author":"Martins Rodrigues","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.tranon.2026.102796_bib0065","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1182\/blood-2025-2151","article-title":"Selective germline testing in multiple myeloma patients yields a six-fold increase in actionable cancer predisposition findings: time for screening guidelines?","volume":"146","author":"del Rosal","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0272","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2021-151495","article-title":"Pathogenic germline variants in multiple myeloma","volume":"138","author":"Thibaud","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0273","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood-2023-190878","article-title":"Confirmed pathogenic germline variants in cancer predisposition genes incidentally detected in somatic genomic profiling of multiple myeloma patients","volume":"142","author":"Thibaud","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0136","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2024-207445","article-title":"Prevalence and clinical implications of germline variants in multiple Myeloma patients","volume":"144","author":"Kubicki","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0224","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1158\/1055-9965.EPI-15-1193","article-title":"A meta-analysis of multiple myeloma risk regions in African and European ancestry populations identifies putatively functional loci","volume":"25","author":"Rand","year":"2016","journal-title":"Cancer Epidemiol. Biomarkers Prevent."},{"key":"10.1016\/j.tranon.2026.102796_bib0251","article-title":"Risk of multiple myeloma in rheumatoid arthritis: a meta-analysis of case-control and cohort studies","volume":"9","author":"Shen","year":"2014","journal-title":"PLoS. One"},{"key":"10.1016\/j.tranon.2026.102796_bib0289","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2014.118786","article-title":"The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells","volume":"100","author":"Weinhold","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0187","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12050","article-title":"Genome-wide association study identifies multiple susceptibility loci for multiple myeloma","volume":"7","author":"Mitchell","year":"2016","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0051","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-019-0329-2","article-title":"Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma","volume":"2","author":"Chattopadhyay","year":"2019","journal-title":"Commun. Biol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0291","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1038\/s41467-018-04989-w","article-title":"Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma","volume":"9","author":"Went","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102796_bib0304","article-title":"Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients","volume":"6","author":"Ziv","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102796_bib0039","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.29101","article-title":"Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length","volume":"136","author":"Campa","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.tranon.2026.102796_bib0041","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41431-021-00986-8","article-title":"A polygenic risk score for multiple myeloma risk prediction","volume":"30","author":"Canzian","year":"2021","journal-title":"Eur. J. Human Genetics"},{"issue":"3","key":"10.1016\/j.tranon.2026.102796_bib0137","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41576-025-00900-8","article-title":"Clinical use of polygenic risk scores: current status, barriers and future directions","volume":"27","author":"Kullo","year":"2025","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0149","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-020-00742-5","article-title":"Polygenic risk scores: from research tools to clinical instruments","volume":"12","author":"Lewis","year":"2020","journal-title":"Genome Med."},{"key":"10.1016\/j.tranon.2026.102796_bib0286","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-biodatasci-111721-074830","article-title":"Challenges and opportunities for developing more generalizable polygenic risk scores","volume":"5","author":"Wang","year":"2022","journal-title":"Annu Rev. Biomed. Data Sci."},{"key":"10.1016\/j.tranon.2026.102796_bib0060","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddn263","article-title":"Genome-wide association studies: implications for multiethnic samples","volume":"17","author":"Cooper","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tranon.2026.102796_bib0208","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.cell.2019.08.051","article-title":"Genome-wide Association Studies in ancestrally diverse populations: opportunities, methods, pitfalls, and recommendations","volume":"179","author":"Peterson","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2026.102796_bib0267","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41576-019-0127-1","article-title":"Benefits and limitations of genome-wide association studies","volume":"20","author":"Tam","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.tranon.2026.102796_bib0053","doi-asserted-by":"crossref","first-page":"9","DOI":"10.46701\/BG.2020012020103","article-title":"Genetic predisposition to multiple myeloma","volume":"4","author":"Cheng","year":"2020","journal-title":"Blood Genom."},{"key":"10.1016\/j.tranon.2026.102796_bib0116","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2019.00424","article-title":"Germline risk contribution to genomic instability in multiple myeloma","volume":"10","author":"Janz","year":"2019","journal-title":"Front. Genet."},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0169","doi-asserted-by":"crossref","DOI":"10.1007\/s13679-025-00644-w","article-title":"Unraveling obesity and multiple myeloma: insights from epidemiology and molecular mechanisms","volume":"14","author":"Manna","year":"2025","journal-title":"Curr. Obes. Rep."},{"key":"10.1016\/j.tranon.2026.102796_bib0221","first-page":"573","article-title":"The genetic and molecular drivers of Multiple myeloma: current insights, clinical implications, and the path forward","volume":"17","author":"Ram","year":"2024","journal-title":"Pharmgenomics. Pers. Med."},{"key":"10.1016\/j.tranon.2026.102796_bib0181","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1182\/blood.2024026313","article-title":"Evolution of multiple myeloma from a genomic perspective","volume":"147","author":"Maura","year":"2026","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.tranon.2026.102796_bib0001","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-020-00348-5","article-title":"Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response","volume":"10","author":"Abdallah","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tranon.2026.102796_bib0083","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.dnarep.2006.05.012","article-title":"Distinguishing primary and secondary translocations in multiple myeloma","volume":"5","author":"Gabrea","year":"2006","journal-title":"DNa Repair. (Amst)"},{"key":"10.1016\/j.tranon.2026.102796_bib0124","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1159\/000529191","article-title":"Cytogenetic abnormalities in multiple myeloma: incidence, prognostic significance, and geographic heterogeneity in Indian and Western populations","volume":"162","author":"Kadam Amare","year":"2023","journal-title":"Cytogenet. Genome Res."},{"key":"10.1016\/j.tranon.2026.102796_bib0217","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of cytogenetic results in multiple myeloma for clinical practice","volume":"5","author":"Rajan","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tranon.2026.102796_bib0146","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1038\/sj.onc.1204641","article-title":"Chromosome translocations in multiple myeloma","volume":"20","author":"Leif Bergsagel","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.tranon.2026.102796_bib0011","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/(SICI)1098-2264(199901)24:1<9::AID-GCC2>3.0.CO;2-K","article-title":"High incidence of cryptic translocations involving the ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization","volume":"24","author":"Avet-Loiseau","year":"1999","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.tranon.2026.102796_bib0082","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1046\/j.1365-2141.1998.00700.x","article-title":"Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases","volume":"101","author":"Fonseca","year":"1998","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tranon.2026.102796_bib0067","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.934008","article-title":"Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation","volume":"12","author":"Diamantidis","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tranon.2026.102796_bib0190","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1182\/blood-2002-03-0749","article-title":"Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy","volume":"100","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0184","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (msmart) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.tranon.2026.102796_bib0047","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjh.18243","article-title":"How do we manage t(11;14) plasma cell disorders with venetoclax?","volume":"199","author":"Chakraborty","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.tranon.2026.102796_bib0125","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2012.37","article-title":"The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies","volume":"2","author":"Kalff","year":"2012","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tranon.2026.102796_bib0193","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.6","article-title":"t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs","volume":"5","author":"Narita","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tranon.2026.102796_bib0250","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/blood.V98.1.217","article-title":"Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma","volume":"98","author":"Shaughnessy","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0111","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1535-6108(04)00019-4","article-title":"Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma","volume":"5","author":"Hurt","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2026.102796_bib0014","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1182\/blood-2010-07-295105","article-title":"Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?","volume":"117","author":"Avet-Loiseau","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0284","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102796_bib0300","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0013","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood.V98.10.3082","article-title":"Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors","volume":"98","author":"Avet-Loiseau","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0009","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0118","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003521","article-title":"Prognostic impact of cytogenetic abnormalities in multiple myeloma: a retrospective analysis of 229 patients","volume":"95","author":"Jian","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.tranon.2026.102796_bib0205","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1182\/blood-2014-07-584268","article-title":"Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations","volume":"125","author":"Pawlyn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0257","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood.V98.7.2229","article-title":"Hypodiploidy is a major prognostic factor in multiple myeloma","volume":"98","author":"Smadja","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0249","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10245330512331390140","article-title":"Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma","volume":"10","author":"Shaughnessy","year":"2005","journal-title":"Hematology."},{"key":"10.1016\/j.tranon.2026.102796_bib0032","doi-asserted-by":"crossref","first-page":"7776","DOI":"10.1158\/1078-0432.CCR-11-1791","article-title":"Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival","volume":"17","author":"Boyd","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102796_bib0055","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1158\/0008-5472.CAN-06-4046","article-title":"Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling","volume":"67","author":"Chng","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2026.102796_bib0243","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cancergencyto.2005.10.016","article-title":"Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance","volume":"167","author":"Schmidt-Wolf","year":"2006","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.tranon.2026.102796_bib0099","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3390\/cancers13020256","article-title":"Gain\/amplification of chromosome arm 1q21 in multiple myeloma","volume":"13","author":"Hanamura","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2026.102796_bib0100","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantati\u2026","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0081","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","article-title":"Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma","volume":"20","author":"Fonseca","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.102796_bib0178","first-page":"26","article-title":"Chromosome 1 abnormalities in multiple myeloma","author":"Marzin","year":"2006","journal-title":"Anticancer Res."},{"key":"10.1016\/j.tranon.2026.102796_bib0048","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.3109\/10428194.2010.524325","article-title":"Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone","volume":"51","author":"Chang","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.tranon.2026.102796_bib0282","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2010-04-279596","article-title":"A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.tranon.2026.102796_bib0080","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.leu.2402125","article-title":"Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy","volume":"15","author":"Fonseca","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.102796_bib0030","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/leu.2011.204","article-title":"A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial","volume":"26","author":"Boyd","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.102796_bib0196","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3324\/haematol.2009.016436","article-title":"Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation","volume":"95","author":"Neben","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.tranon.2026.102796_bib0079","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0275","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2008.4","article-title":"Genetic aberrations and survival in plasma cell leukemia","volume":"22","author":"Tiedemann","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.102796_bib0167","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102796_bib0200","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging system for Multiple Myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102796_bib0054","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/ijlh.12360","article-title":"Advances in the pathogenesis and diagnosis of multiple myeloma","volume":"37","author":"Chesi","year":"2015","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.tranon.2026.102796_bib0096","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2004-04-1319","article-title":"Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma","volume":"104","author":"Guti\u00e9rrez","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.tranon.2026.102796_bib0003","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/leu.2014.70","article-title":"Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma","volume":"28","author":"Affer","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.102796_bib0288","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2015.136929","article-title":"Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma","volume":"101","author":"Weinhold","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.tranon.2026.102796_bib0283","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.13","article-title":"Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients","volume":"4","author":"Walker","year":"2014","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0027","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102796_bib0049","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/10428190310001638832","article-title":"Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis","volume":"45","author":"Chang","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.tranon.2026.102796_bib0103","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/MAJ.0b013e31825b32bc","article-title":"A retrospective analysis of cytogenetic and clinical characteristics in patients with multiple myeloma","volume":"345","author":"He","year":"2013","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.tranon.2026.102796_bib0215","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/jclinpath-2015-203054","article-title":"Genomic profiling of myeloma: the best approach, a comparison of cytogenetics, FISH and array-CGH of 112 myeloma cases","volume":"69","author":"Rack","year":"2016","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.tranon.2026.102796_bib0092","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5603\/AHP.2021.0004","article-title":"Clinical implications of cytogenetic and molecular aberrations in multiple myeloma","volume":"52","author":"Goldman-Mazur","year":"2021","journal-title":"Acta Haematol. Pol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0264","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13046-017-0591-4","article-title":"High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods","volume":"36","author":"Su","year":"2017","journal-title":"J. Experim. Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102796_bib0057","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1182\/blood-2025-7479","article-title":"Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: the flagship study","volume":"146","author":"Coffey","year":"2025","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.tranon.2026.102796_bib0297","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41408-019-0264-y","article-title":"Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma","volume":"9","author":"Yellapantula","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tranon.2026.102796_bib0089","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.3390\/cancers15194687","article-title":"Optical genome mapping reveals the complex genetic landscape of myeloma","volume":"15","author":"Gigu\u00e8re","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2026.102796_bib0296","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood-2024-212346","article-title":"Unveiling clinical potential: exploring cytogenomic aberrations through optical genomic mapping in multiple myeloma","volume":"144","author":"Ye","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0298","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/ajh.27589","article-title":"Clinical validation of optical genome mapping in multiple myeloma without plasma cell enrichment","volume":"100","author":"Yoon","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tranon.2026.102796_bib0212","first-page":"083","article-title":"Optical genome mapping: technical basis and applications in hematological malignancies","volume":"42","author":"Puiggros","year":"2023","journal-title":"Revista Sangre"},{"key":"10.1016\/j.tranon.2026.102796_bib0148","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3390\/genes16080924","article-title":"Optical genome mapping: a new tool for cytogenomic analysis","volume":"16","author":"Levy","year":"2025","journal-title":"Genes"},{"key":"10.1016\/j.tranon.2026.102796_bib0016","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/nar\/gkad1183","article-title":"Enhancer\u2013promoter interactions can form independently of genomic distance and be functional across TAD boundaries","volume":"52","author":"Balasubramanian","year":"2024","journal-title":"Nucleic. Acids. Res."},{"key":"10.1016\/j.tranon.2026.102796_bib0043","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3390\/cells10020336","article-title":"Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications","volume":"10","author":"Cardona-benavides","year":"2021","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.tranon.2026.102796_bib0072","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41571-021-00593-y","article-title":"Single-cell profiling of tumour evolution in multiple myeloma \u2014 Opportunities for precision medicine","volume":"19","author":"Dutta","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0293","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1038\/s41467-017-01793-w","article-title":"3D genome of multiple myeloma reveals spatial genome disorganization associated with copy number variations","volume":"8","author":"Wu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102796_bib0185","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3324\/haematol.2017.163766","article-title":"The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma","volume":"102","author":"Mikulasova","year":"2017","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.tranon.2026.102796_bib0107","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-019-0221-9","article-title":"Mutational processes contributing to the development of multiple myeloma","volume":"9","author":"Hoang","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tranon.2026.102796_bib0237","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nmeth.2883","article-title":"PyClone: statistical inference of clonal population structure in cancer","volume":"11","author":"Roth","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.tranon.2026.102796_bib0026","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.V122.21.399.399","article-title":"Whole exome sequencing of multiple myeloma reveals an heterogeneous clonal architecture and genomic evolution","volume":"122","author":"Bolli","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0179","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102796_bib0225","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1182\/blood-2014-04-569327","article-title":"Differential and limited expression of mutant alleles in multiple myeloma","volume":"124","author":"Rashid","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.tranon.2026.102796_bib0145","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2012.47","article-title":"Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules","volume":"3","author":"Leich","year":"2013","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tranon.2026.102796_bib0135","doi-asserted-by":"crossref","first-page":"80664","DOI":"10.18632\/oncotarget.13025","article-title":"Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse","volume":"7","author":"Krzeminski","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.tranon.2026.102796_bib0176","first-page":"625","article-title":"Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review)","volume":"40","author":"Martino","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.tranon.2026.102796_bib0076","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1182\/blood-2014-07-586701","article-title":"Genome-wide scan identifies variant in 2q12.3 associated with risk for multiple myeloma","volume":"124","author":"Erickson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0070","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/bloodadvances.2019000491","article-title":"A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry","volume":"4","author":"Du","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0290","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.1038\/s41467-024-50932-7","article-title":"Deciphering the genetics and mechanisms of predisposition to multiple myeloma","volume":"15","author":"Went","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102796_bib0038","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2141.2012.09047.x","article-title":"Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium","volume":"157","author":"Campa","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tranon.2026.102796_bib0174","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1365-2141.2012.09244.x","article-title":"Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma","volume":"158","author":"Martino","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tranon.2026.102796_bib0175","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/1055-9965.EPI-13-1115","article-title":"Genetic variants and multiple myeloma risk: iMMEnSE validation of the best reported associations\u2013an extensive replication of the associations from the candidate gene era","volume":"23","author":"Martino","year":"2014","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.tranon.2026.102796_bib0056","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.3390\/ijms24108500","article-title":"Polymorphisms within autophagy-related genes as susceptibility biomarkers for multiple myeloma: a meta-analysis of three large cohorts and functional characterization","volume":"24","author":"Clavero","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2026.102796_bib0230","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.10665","article-title":"A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis","volume":"7","author":"R\u00edos-Tamayo","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.tranon.2026.102796_bib0075","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/annonc\/mdr324","article-title":"The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma","volume":"23","author":"Er\u010dulj","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2026.102796_bib0061","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2003-02-0444","article-title":"Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma","volume":"102","author":"Dasgupta","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0295","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.biopha.2017.08.142","article-title":"MDR1 polymorphisms affect the outcome of Chinese multiple myeloma patients","volume":"95","author":"Xiao","year":"2017","journal-title":"Biomedicine and Pharmacotherapy"},{"key":"10.1016\/j.tranon.2026.102796_bib0160","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bjh.15521","article-title":"Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients","volume":"183","author":"Macauda","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tranon.2026.102796_bib0227","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/10245332.2018.1443897","article-title":"Multidrug resistance 1 (MDR1\/ABCB1) gene polymorphism (rs1045642 C\u2009>\u2009T) and susceptibility to multiple myeloma: a systematic review and meta-analysis","volume":"23","author":"Razi","year":"2018","journal-title":"Hematology."},{"key":"10.1016\/j.tranon.2026.102796_bib0173","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/leu.2011.352","article-title":"Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium","volume":"26","author":"Martino","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.102796_bib0112","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1080\/10428194.2019.1689391","article-title":"Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed\/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium","volume":"61","author":"Iskierka-Ja\u017cd\u017cewska","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.tranon.2026.102796_bib0113","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood.V124.21.3628.3628","article-title":"Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in multiple myeloma patients treated with lenalidomide: a pharmacogenetic study of Immense Consortium","volume":"124","author":"Iskierka-Jazdzewska","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0266","doi-asserted-by":"crossref","first-page":"24054","DOI":"10.18632\/oncotarget.25307","article-title":"Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients","volume":"9","author":"Szudy-Szczyrek","year":"2018","journal-title":"Oncotarget."},{"key":"10.1016\/j.tranon.2026.102796_bib0303","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/7569809","article-title":"The genetic polymorphisms of NLRP3 inflammasome associated with T helper cells in patients with multiple myeloma","author":"Zhao","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.tranon.2026.102796_bib0248","first-page":"212","article-title":"Association between interleukin gene polymorphisms and multiple myeloma susceptibility","volume":"12","author":"Shahzad","year":"2020","journal-title":"Mol. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-04082-2","article-title":"The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression","volume":"9","author":"Ali","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0265","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.1038\/ncomms8213","article-title":"Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma","volume":"6","author":"Swaminathan","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102796_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.27387","article-title":"Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma","volume":"131","author":"Andersen","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tranon.2026.102796_bib0156","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.58","article-title":"VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens","volume":"7","author":"Lopes-Aguiar","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tranon.2026.102796_bib0037","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1080\/10428194.2018.1551536","article-title":"Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study","volume":"60","author":"Campa","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.tranon.2026.102796_bib0020","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1038\/leu.2016.199","article-title":"HLA polymorphism and risk of multiple myeloma","volume":"30","author":"Beksac","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.tranon.2026.102796_bib0019","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00251-024-01336-w","article-title":"HLA class I NK-epitopes and KIR diversities in patients with multiple myeloma","volume":"76","author":"Beelen","year":"2024","journal-title":"Immunogenetics"},{"key":"10.1016\/j.tranon.2026.102796_bib0172","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1093721","article-title":"Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing","volume":"5","author":"Mart\u00ednez-S\u00e1nchez","year":"2016","journal-title":"Oncoimmunology."},{"issue":"11","key":"10.1016\/j.tranon.2026.102796_bib0158","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/s41375-023-02022-8","article-title":"Identification of novel genetic loci for risk of multiple myeloma by functional annotation","volume":"37","author":"Macauda","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.102796_bib0161","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ijc.33547","article-title":"Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients","volume":"149","author":"Macauda","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tranon.2026.102796_bib0183","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1002\/ijc.33377","article-title":"Common gene variants within 3\u2019-untranslated regions as modulators of multiple myeloma risk and survival","volume":"148","author":"Melaiu","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tranon.2026.102796_bib0077","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1158\/1078-0432.CCR-12-0191","article-title":"Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation","volume":"18","author":"Fern\u00e1ndez De Larrea","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102796_bib0159","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/ijc.30465","article-title":"Identification of miRSNPs associated with the risk of multiple myeloma","volume":"140","author":"Macauda","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tranon.2026.102796_bib0242","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3324\/haematol.10618","article-title":"Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma","volume":"92","author":"Schilthuizen","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.tranon.2026.102796_bib0209","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.3390\/cancers15164155","article-title":"Understanding DNA damage response and DNA repair in multiple myeloma","volume":"15","author":"Petrilla","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2026.102796_bib0240","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3390\/cancers13030504","article-title":"DNA damage response in multiple myeloma: the role of the tumor microenvironment","volume":"13","author":"Saitoh","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2026.102796_bib0126","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.18632\/oncotarget.1740","article-title":"A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy","volume":"5","author":"Kassambara","year":"2014","journal-title":"Oncotarget."},{"key":"10.1016\/j.tranon.2026.102796_bib0046","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1182\/blood-2015-06-649970","article-title":"Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells","volume":"127","author":"Cea","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0151","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1179\/1607845415Y.0000000029","article-title":"Dysregulation of the NLRP3 inflammasome complex and related cytokines in patients with multiple myeloma","volume":"21","author":"Li","year":"2016","journal-title":"Hematology."},{"key":"10.1016\/j.tranon.2026.102796_bib0108","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.immuni.2021.07.002","article-title":"\u03b22-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression","volume":"54","author":"Hofbauer","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.tranon.2026.102796_bib0204","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.4049\/jimmunol.1401608","article-title":"Transcription elongation factor ELL2 drives ig secretory-specific mRNA production and the unfolded protein response","volume":"193","author":"Park","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.tranon.2026.102796_bib0219","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin. Proc."},{"issue":"8","key":"10.1016\/j.tranon.2026.102796_bib0033","first-page":"1363","article-title":"Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma","volume":"93","author":"Brito","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.tranon.2026.102796_bib0276","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-genom-091212-153455","article-title":"Major histocompatibility complex genomics and human disease","volume":"14","author":"Trowsdale","year":"2013","journal-title":"Annu Rev. Genomics. Hum. Genet."},{"key":"10.1016\/j.tranon.2026.102796_bib0164","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02848","article-title":"Tuning natural killer cell anti-multiple myeloma reactivity by targeting inhibitory signaling via KIR and NKG2A","volume":"9","author":"Mahaweni","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tranon.2026.102796_bib0199","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.seminoncol.2018.01.004","article-title":"Proteasome inhibitors: structure and function","volume":"44","author":"Nunes","year":"2018","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.tranon.2026.102796_bib0023","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.chembiol.2018.11.007","article-title":"Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available Proteasome inhibitors","volume":"26","author":"Besse","year":"2019","journal-title":"Cell Chem. Biol."},{"issue":"4","key":"10.1016\/j.tranon.2026.102796_bib0084","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev."},{"issue":"6","key":"10.1016\/j.tranon.2026.102796_bib0188","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.56","article-title":"A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma","volume":"7","author":"Mitra","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tranon.2026.102796_bib0285","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1158\/1078-0432.CCR-07-5150","article-title":"Proteasome \u03b2 subunit pharmacogenomics: gene resequencing and functional genomics","volume":"14","author":"Wang","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102796_bib0154","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3324\/haematol.2011.043331","article-title":"Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1","volume":"97","author":"Ling","year":"2012","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.tranon.2026.102796_bib0229","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12185-016-2016-0","article-title":"Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma","volume":"104","author":"Ri","year":"2016","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.tranon.2026.102796_bib0106","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells","volume":"114","author":"Hideshima","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0260","article-title":"Influence of PSMB6 and PSMB9 genetic polymorphisms on bortezomib-based therapy response in newly diagnosed multiple myeloma","volume":"17","author":"Sood","year":"2025","journal-title":"Cureus."},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0244","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s10238-025-01713-z","article-title":"Impact of proteostasis workload on sensitivity to proteasome inhibitors in multiple myeloma","volume":"25","author":"Sedlacek","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.tranon.2026.102796_bib0132","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kort\u00fcm","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0281","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2023.06.315","article-title":"3208 \u2013 Unravelling drug resistance and sensitization to proteasome inhibitors using genome-wide Crispr-Cas9 knockout screening","volume":"124","author":"Vlayen","year":"2023","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.tranon.2026.102796_bib0117","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.740796","article-title":"Carfilzomib: a promising proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma","volume":"11","author":"Jayaweera","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0255","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00280-017-3323-8","article-title":"Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms","volume":"80","author":"Sissung","year":"2017","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.tranon.2026.102796_bib0192","first-page":"217","article-title":"Spotlight on ixazomib: potential in the treatment of multiple myeloma","volume":"10","author":"Muz","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.tranon.2026.102796_bib0226","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1158\/0008-5472.CAN-15-2477","article-title":"Proteasomal inhibition by Ixazomib induces CHK1 and MYC dependent cell death in T-cell and Hodgkin lymphoma","volume":"76","author":"Ravi","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2026.102796_bib0028","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/ajh.24895","article-title":"A single center Phase II study of Ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas","volume":"92","author":"Boonstra","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tranon.2026.102796_bib0062","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/ejh.13435","article-title":"Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-\u03bab pathway activation","volume":"105","author":"Dash","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.tranon.2026.102796_bib0191","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102796_bib0259","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0010","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1182\/blood-2017-06-791228","article-title":"Ixazomib significantly prolongs progression-free survival in high-risk relapsed\/refractory myeloma patients","volume":"130","author":"Avet-Loiseau","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0050","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/abbs\/gmt142","article-title":"Mechanism of immunomodulatory drugs\u2019 action in the treatment of multiple myeloma","volume":"46","author":"Chang","year":"2014","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"key":"10.1016\/j.tranon.2026.102796_bib0002","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/jjco\/hyz083","article-title":"Immunomodulatory drugs in the treatment of multiple myeloma","volume":"49","author":"Abe","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102796_bib0214","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.102796_bib0018","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2019.217943","article-title":"IKZF1\/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma","volume":"105","author":"Barrio","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.tranon.2026.102796_bib0093","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood.2020007081","article-title":"Multiple Cereblon genetic changes associate with acquired resistance to Lenalidomide or Pomalidomide in Multiple Myeloma","volume":"137","author":"Gooding","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0097","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/1078-0432.CCR-22-1161","article-title":"Single-nucleotide variants and epimutations induce proteasome inhibitor resistance in multiple myeloma","volume":"29","author":"Haertle","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102796_bib0029","first-page":"13","article-title":"Mechanisms of immune evasion in multiple myeloma: open questions and therapeutic opportunities","author":"Botta","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2026.102796_bib0235","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/198539","article-title":"Immunological dysregulation in multiple myeloma microenvironment","author":"Romano","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.tranon.2026.102796_bib0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bjh.13786","article-title":"TLR4\/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma","volume":"172","author":"Bagratuni","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0109","article-title":"Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide","volume":"9","author":"Huang","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tranon.2026.102796_bib0058","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1158\/1078-0432.CCR-19-2111","article-title":"How to train your T cells: overcoming immune dysfunction in multiple myeloma a C","volume":"26","author":"Cohen","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102796_bib0071","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.tranon.2026.102796_bib0133","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0171","doi-asserted-by":"crossref","unstructured":"Marone, R., Asllanaj, E., Capoferri, G., Schwede, T., Jeker, L.T., Lepore, R., 2025. Impact of Human genetic variation underlying resistance to antigen-specific immunotherapy. bioRxiv 2025.05.02.651174. https:\/\/doi.org\/10.1101\/2025.05.02.651174.","DOI":"10.1101\/2025.05.02.651174"},{"key":"10.1016\/j.tranon.2026.102796_bib0246","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.7150\/thno.52614","article-title":"The current landscape of antibody-based therapies in solid malignancies","volume":"11","author":"Shah","year":"2021","journal-title":"Theranostics."},{"key":"10.1016\/j.tranon.2026.102796_bib0279","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(24)00186-8","article-title":"Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies","volume":"11","author":"van de Donk","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.tranon.2026.102796_bib0213","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.apsb.2024.03.027","article-title":"Stepping forward: t-cell redirecting bispecific antibodies in cancer therapy","volume":"14","author":"Qin","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0241","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.tranon.2026.102796_bib0143","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2026.102796_bib0078","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.2023023557","article-title":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","volume":"144","author":"Firestone","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0203","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1158\/2643-3230.BCD-25-0005","article-title":"Timing genomic antigen loss in multiple myeloma treated with T cell-redirecting immunotherapies","volume":"6","author":"Papadimitriou","year":"2025","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.tranon.2026.102796_bib0268","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/cells14141077","article-title":"Resistance mechanisms to BCMA targeting bispecific antibodies and CAR T-cell therapies in multiple myeloma","volume":"14","author":"Tedder","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.tranon.2026.102796_bib0263","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/antib8030041","article-title":"Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells","volume":"8","author":"Strohl","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.tranon.2026.102796_bib0153","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117252","article-title":"Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies","volume":"178","author":"Lin","year":"2024","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1016\/j.tranon.2026.102796_bib0165","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from car t-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tranon.2026.102796_bib0239","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12185-023-03579-x","article-title":"Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy","volume":"117","author":"Russell","year":"2023","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.tranon.2026.102796_bib0280","article-title":"Aging-associated immune system changes in multiple myeloma: the dark side of the moon","volume":"29","author":"Visram","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.tranon.2026.102796_bib0115","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.coph.2013.04.006","article-title":"Tumour heterogeneity and immune-modulation","volume":"13","author":"Jamal-Hanjani","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102796_bib0228","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41525-017-0013-8","article-title":"Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma","volume":"2","author":"Reuben","year":"2017","journal-title":"NPJ. Genom. Med."},{"key":"10.1016\/j.tranon.2026.102796_bib0131","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/path.5681","article-title":"Microenvironmental regulation of tumour immunity and response to immunotherapy","volume":"254","author":"Kockx","year":"2021","journal-title":"J. Pathol."},{"key":"10.1016\/j.tranon.2026.102796_bib0017","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.1038\/s41467-022-34041-x","article-title":"DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response","volume":"13","author":"Baldwin","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102796_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1291920","article-title":"Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review","volume":"14","author":"Cao","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tranon.2026.102796_bib0095","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/blood.2020007899","article-title":"Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression","volume":"137","author":"Gupta","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0147","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/jpm11050334","article-title":"Targeted therapies for multiple myeloma","volume":"11","author":"Leow","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.tranon.2026.102796_bib0195","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-016-0282-1","article-title":"Novel agents in the treatment of multiple myeloma: a review about the future","volume":"9","author":"Naymagon","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tranon.2026.102796_bib0073","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3390\/ijms17101760","article-title":"Towards stratified medicine in plasma cell myeloma","volume":"17","author":"Egan","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2026.102796_bib0074","first-page":"2420","article-title":"Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible","volume":"109","author":"Engelhardt","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.tranon.2026.102796_bib0180","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO.23.01277","article-title":"Genomic classification and individualized prognosis in multiple myeloma","volume":"42","author":"Maura","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102796_bib0231","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/ajh.24389","article-title":"Early mortality in multiple myeloma: the time-dependent impact of comorbidity: a population-based study in 621 real-life patients","volume":"91","author":"R\u00edos-Tamayo","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tranon.2026.102796_bib0004","first-page":"13","article-title":"Genome instability in multiple myeloma: facts and factors","author":"Aksenova","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2026.102796_bib0128","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/bjh.16764","article-title":"The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?","volume":"191","author":"Kazandjian","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tranon.2026.102796_bib0194","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/bcp.12906","article-title":"High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation","volume":"82","author":"Nath","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.tranon.2026.102796_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01155","article-title":"Targeted therapy with immunoconjugates for multiple myeloma","volume":"11","author":"Bruins","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tranon.2026.102796_bib0274","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2174\/1568026043387638","article-title":"Pharmacogenomics: the influence of genomic variation on drug response","volume":"4","author":"Thomas","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.tranon.2026.102796_bib0155","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ajem.2024.11.073","article-title":"An emergency medicine review: multiple myeloma and its complications","volume":"88","author":"Long","year":"2025","journal-title":"Am. J. Emergency Med."},{"key":"10.1016\/j.tranon.2026.102796_bib0201","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102796_bib0254","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2643-3230.BCD-24-0103","article-title":"Therapy-related myeloid neoplasms: complex interactions among cytotoxic therapies, genetic factors, and aberrant microenvironment","volume":"5","author":"Singhal","year":"2024","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.tranon.2026.102796_bib0040","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s11064-016-2007-9","article-title":"Genetic susceptibility to Bortezomib-induced peripheral neuroropathy: replication of the reported candidate susceptibility loci","volume":"42","author":"Campo","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.tranon.2026.102796_bib0008","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature","volume":"112","author":"Argyriou","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102796_bib0163","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1158\/1078-0432.CCR-15-3163","article-title":"A genome-wide association study identifies a novel locus for Bortezomib-induced peripheral neuropathy in European patients with multiple myeloma","volume":"22","author":"Magrangeas","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102796_bib0121","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.2010.28.0792","article-title":"Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma","volume":"29","author":"Johnson","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102796_bib0022","first-page":"11","article-title":"Bone disease in multiple myeloma: biologic and clinical implications","author":"Bernstein","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.tranon.2026.102796_bib0102","first-page":"13","article-title":"Myeloma-bone interaction: a vicious cycle via TAK1-PIM2 signaling","author":"Harada","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2026.102796_bib0202","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s11914-017-0397-5","article-title":"Myeloma and bone disease","volume":"15","author":"Panaroni","year":"2017","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.tranon.2026.102796_bib0238","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-03059-8","article-title":"Osteocyte apoptosis: the roles and key molecular mechanisms in resorption-related bone diseases","volume":"11","author":"Ru","year":"2020","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.tranon.2026.102796_bib0271","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.metabol.2017.11.012","article-title":"Biology and treatment of myeloma related bone disease","volume":"80","author":"Terpos","year":"2018","journal-title":"Metabolism."},{"issue":"4","key":"10.1016\/j.tranon.2026.102796_bib0122","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/leu.2015.342","article-title":"Genetic factors influencing the risk of multiple myeloma bone disease","volume":"30","author":"Johnson","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.102796_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2019.09.007","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"19","author":"Bustoros","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.tranon.2026.102796_bib0088","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.bbmt.2014.03.022","article-title":"A single nucleotide polymorphism in SLC7A5 is associated with gastrointestinal toxicity after high-dose melphalan and autologous stem cell transplantation for multiple myeloma","volume":"20","author":"Giglia","year":"2014","journal-title":"Biol. Blood Marrow TransPlant"},{"key":"10.1016\/j.tranon.2026.102796_bib0091","doi-asserted-by":"crossref","first-page":"971","DOI":"10.6004\/jnccn.2009.0064","article-title":"Supportive therapies in multiple myeloma","volume":"7","author":"Gleason","year":"2009","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.tranon.2026.102796_bib0059","first-page":"841","article-title":"GWAS of 972 autologous stem cell recipients with multiple myeloma identifies 11 genetic variants associated with chemotherapy-induced oral mucositis","volume":"23","author":"Coleman","year":"2015","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.tranon.2026.102796_bib0134","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/asheducation-2010.1.437","article-title":"Thrombosis in multiple myeloma","author":"Kristinsson","year":"2010","journal-title":"Hematology. Am. Soc. Hematol. Educ. Program."},{"key":"10.1016\/j.tranon.2026.102796_bib0144","article-title":"Integrative analyses of genes about venous thromboembolism: an umbrella review of systematic reviews and meta-analyses","volume":"101","author":"Lee","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.tranon.2026.102796_bib0253","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10654-013-9825-8","article-title":"Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, prothrombin 20210A and methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls","volume":"28","author":"Simone","year":"2013","journal-title":"Eur. J. Epidemiol."},{"issue":"2","key":"10.1016\/j.tranon.2026.102796_bib0168","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2016","journal-title":"Nature Reviews Clinical Oncology"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326001336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326001336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:45:59Z","timestamp":1783122359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326001336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":292,"alternative-id":["S1936523326001336"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102796","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic architecture of multiple myeloma: From somatic alterations to germline susceptibility and clinical implications","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102796","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102796"}}